Low-dose aspirin is an NSAID that irreversibly inhibits the COX-1 enzyme in platelets, reducing their ability to aggregate and form clots. This mechanism is effective for preventing heart attacks and strokes in individuals with established cardiovascular disease. However, for healthy individuals (primary prevention), large clinical trials have shown this benefit is offset by a significant increase in the risk of major bleeding, making its use for general healthspan extension unfavorable.
Verdict
Not recommended for general healthspan due to significant bleeding risks.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$5 - $15
Protocol
- A typical dose is 81 mg taken orally once daily.
Flags
- Increased risk of major gastrointestinal bleeding, which can be life-threatening.
- Increased risk of hemorrhagic stroke (bleeding in the brain).
- Recent guidelines (e.g., USPSTF) advise against routine use for primary prevention in most adults.
- Interacts with other anticoagulants (e.g., warfarin), NSAIDs, and alcohol, increasing bleeding risk.
- Should not be taken by individuals with bleeding disorders or active ulcers.